UNSPSC 51342316: Valganciclovir hydrochloride

This classification denotes the hydrochloride form of a purine antagonist and antiviral agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCU97FKN3R. European Medicines Agency schedules Valganciclovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00007MIG. Valganciclovir generally arises in the molecular formula C14H22N6O5.

UNSPSC 51342316 Valganciclovir hydrochloride is a Commodity code that shows minimal recent state and local procurement activity directly aligned with the pharmaceutical product itself. The recent opportunities tagged under this code reflect a significant mismatch: the actual buying activity involves broader medical and pharmaceutical procurement categories—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription program exploration—rather than the antiviral treatment valganciclovir specifically. State and local governments acquiring under this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and cooperative purchasing alliances serving multi-state public-sector networks (Minnesota Multistate Cooperative Purchasing Alliance for Oregon and Minnesota participants). The issuing bodies indicate demand from both individual procurement jurisdictions executing single-entity solicitations and state-administered cooperative purchasing vehicles that aggregate buying power across multiple states and local governments.

Recent opportunities show activity concentrated in Florida, Texas, Minnesota, and Oregon, with procurement mechanisms ranging from competitive sealed bidding (IFB) and formal requests for proposal (RFP) to preliminary requests for information (RFI) that inform future procurement strategy. The City of Tampa's March 2026 IFB for medical and first aid supplies (26P00145) sought 169 line items for the Fire Department Rescue Division with an estimated contract value of $700,000 and a March 13, 2026 deadline, designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products required proposals by March 26, 2026, with two-year initial terms and optional extensions, mandating pricing submission through three authorized wholesalers and compliance with cGMP and DSCSA. The Texas HHS Commission's April 2026 RFI (HHS0017013) explored vendor capabilities for direct-to-manufacturer prescription programs as preliminary market intelligence before formal solicitation. Seminole County's June 2026 IFB (IFB60459723LAS) procured naloxone and safe drug deactivation systems with annual quantities of 1,900 and 800 units respectively and a July 26, 2023 deadline.